U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
139594
Substance Class Protein
Created
by admin
on Sat Dec 16 11:23:10 GMT 2023
Edited
by admin
on Sat Dec 16 11:23:10 GMT 2023
Protein Type BISPECIFIC ANTIBODY
Protein Sub Type IMMUNOGLOBULIN RECOMBINED G1-KAPPA/LAMBDA
Sequence Origin HUMANIZED
Sequence Type COMPLETE
Record UNII
B800Z06O8K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VANUCIZUMAB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
C0U97738AE
Common Name English
IMMUNOGLOBULIN RECOMBINED G1-KAPPA/LAMBDA, ANTI-(HOMO SAPIENS ANGPT2 (ANGIOPOIETIN 2, ANG2))/ANTI-HOMO SAPIENS VEGFA (VASCULAR ENDOTHELIAL GROWTH FACTOR A, VEGF-A, VEGF)), HUMANIZED MONOCLONAL ANTIBODY
Common Name English
BISPECIFIC HUMAN ANTI-ANG-2/ANTI-VEGF-A MONOCLONAL ANTIBODY
Common Name English
RG7221
Code English
RG-7221
Code English
vanucizumab [INN]
Common Name English
Vanucizumab [WHO-DD]
Common Name English
BISPECIFIC HUMAN ANTI-ANG-2/ANTI-VEGF-A ANTIBODY
Common Name English
RO5520985
Code English
RO-5520985
Code English
VANUCIZUMAB [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1742
Created by admin on Sat Dec 16 11:23:10 GMT 2023 , Edited by admin on Sat Dec 16 11:23:10 GMT 2023
NCI_THESAURUS C129822
Created by admin on Sat Dec 16 11:23:10 GMT 2023 , Edited by admin on Sat Dec 16 11:23:10 GMT 2023
NCI_THESAURUS C1454
Created by admin on Sat Dec 16 11:23:10 GMT 2023 , Edited by admin on Sat Dec 16 11:23:10 GMT 2023
Code System Code Type Description
FDA UNII
B800Z06O8K
Created by admin on Sat Dec 16 11:23:10 GMT 2023 , Edited by admin on Sat Dec 16 11:23:10 GMT 2023
PRIMARY
DRUG BANK
DB12317
Created by admin on Sat Dec 16 11:23:10 GMT 2023 , Edited by admin on Sat Dec 16 11:23:10 GMT 2023
PRIMARY
WIKIPEDIA
Vanucizumab
Created by admin on Sat Dec 16 11:23:10 GMT 2023 , Edited by admin on Sat Dec 16 11:23:10 GMT 2023
PRIMARY
CAS
1448221-05-3
Created by admin on Sat Dec 16 11:23:10 GMT 2023 , Edited by admin on Sat Dec 16 11:23:10 GMT 2023
PRIMARY
NCI_THESAURUS
C118578
Created by admin on Sat Dec 16 11:23:10 GMT 2023 , Edited by admin on Sat Dec 16 11:23:10 GMT 2023
PRIMARY
USAN
CD-98
Created by admin on Sat Dec 16 11:23:10 GMT 2023 , Edited by admin on Sat Dec 16 11:23:10 GMT 2023
PRIMARY
INN
9950
Created by admin on Sat Dec 16 11:23:10 GMT 2023 , Edited by admin on Sat Dec 16 11:23:10 GMT 2023
PRIMARY
ChEMBL
CHEMBL3545259
Created by admin on Sat Dec 16 11:23:10 GMT 2023 , Edited by admin on Sat Dec 16 11:23:10 GMT 2023
PRIMARY
EVMPD
SUB177209
Created by admin on Sat Dec 16 11:23:10 GMT 2023 , Edited by admin on Sat Dec 16 11:23:10 GMT 2023
PRIMARY
From To
1_22 1_96
1_156 1_216
1_277 1_337
1_383 1_441
2_22 2_96
2_150 2_206
2_267 2_327
2_373 2_431
3_22 3_87
3_137 3_193
4_23 4_88
4_134 4_194
1_236 3_213
2_226 4_214
1_242 2_232
1_245 2_235
1_365 2_360
Glycosylation Link Type Site
N 1_313
N 2_303
Related Record Type Details
HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A
TARGET -> INHIBITOR
ANGIOPOIETIN-2
TARGET -> INHIBITOR
Related Record Type Details
VANUCIZUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966